These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 39416967)

  • 1. A Novel Liver Cancer-Selective Histone Deacetylase Inhibitor Is Effective against Hepatocellular Carcinoma and Induces Durable Responses with Immunotherapy.
    Wu B; Tapadar S; Ruan Z; Sun CQ; Arnold RS; Johnston A; Olugbami JO; Arunsi U; Gaul DA; Petros JA; Kobayashi T; Duda DG; Oyelere AK
    ACS Pharmacol Transl Sci; 2024 Oct; 7(10):3155-3169. PubMed ID: 39416967
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Novel Liver Cancer-Selective Histone Deacetylase Inhibitor Is Effective Against Hepatocellular Carcinoma and Induces Durable Responses with Immunotherapy.
    Wu B; Tapadar S; Ruan Z; Sun C; Arnold R; Johnston A; Olugbami J; Arunsi U; Gaul D; Petros J; Kobayashi T; Duda DG; Oyelere AK
    bioRxiv; 2024 Jun; ():. PubMed ID: 38585757
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Histone Deacetylase Expressions in Hepatocellular Carcinoma and Functional Effects of Histone Deacetylase Inhibitors on Liver Cancer Cells In Vitro.
    Freese K; Seitz T; Dietrich P; Lee SML; Thasler WE; Bosserhoff A; Hellerbrand C
    Cancers (Basel); 2019 Oct; 11(10):. PubMed ID: 31635225
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Liver-Targeting Class I Selective Histone Deacetylase Inhibitors Potently Suppress Hepatocellular Tumor Growth as Standalone Agents.
    Tapadar S; Fathi S; Wu B; Sun CQ; Raji I; Moore SG; Arnold RS; Gaul DA; Petros JA; Oyelere AK
    Cancers (Basel); 2020 Oct; 12(11):. PubMed ID: 33114147
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thioredoxin-interacting protein-activated intracellular potassium deprivation mediates the anti-tumour effect of a novel histone acetylation inhibitor HL23, a fangchinoline derivative, in human hepatocellular carcinoma.
    Lu Y; Liu Y; Lan J; Chan YT; Feng Z; Huang L; Wang N; Pan W; Feng Y
    J Adv Res; 2023 Sep; 51():181-196. PubMed ID: 36351536
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activated p53 with Histone Deacetylase Inhibitor Enhances L-Fucose-Mediated Drug Delivery through Induction of Fucosyltransferase 8 Expression in Hepatocellular Carcinoma Cells.
    Okagawa Y; Takada K; Arihara Y; Kikuchi S; Osuga T; Nakamura H; Kamihara Y; Hayasaka N; Usami M; Murase K; Miyanishi K; Kobune M; Kato J
    PLoS One; 2016; 11(12):e0168355. PubMed ID: 27977808
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination therapy for hepatocellular carcinoma: additive preclinical efficacy of the HDAC inhibitor panobinostat with sorafenib.
    Lachenmayer A; Toffanin S; Cabellos L; Alsinet C; Hoshida Y; Villanueva A; Minguez B; Tsai HW; Ward SC; Thung S; Friedman SL; Llovet JM
    J Hepatol; 2012 Jun; 56(6):1343-50. PubMed ID: 22322234
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dual targeting of mTORC1/C2 complexes enhances histone deacetylase inhibitor-mediated anti-tumor efficacy in primary HCC cancer in vitro and in vivo.
    Shao H; Gao C; Tang H; Zhang H; Roberts LR; Hylander BL; Repasky EA; Ma WW; Qiu J; Adjei AA; Dy GK; Yu C
    J Hepatol; 2012 Jan; 56(1):176-83. PubMed ID: 21835141
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sorafenib increases efficacy of vorinostat against human hepatocellular carcinoma through transduction inhibition of vorinostat-induced ERK/NF-κB signaling.
    Hsu FT; Liu YC; Chiang IT; Liu RS; Wang HE; Lin WJ; Hwang JJ
    Int J Oncol; 2014 Jul; 45(1):177-88. PubMed ID: 24807012
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel histone deacetylase inhibitor MPT0G009 induces cell apoptosis and synergistic anticancer activity with tumor necrosis factor-related apoptosis-inducing ligand against human hepatocellular carcinoma.
    Chen MC; Huang HH; Lai CY; Lin YJ; Liou JP; Lai MJ; Li YH; Teng CM; Yang CR
    Oncotarget; 2016 Jan; 7(1):402-17. PubMed ID: 26587975
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activation of mPTP-dependent mitochondrial apoptosis pathway by a novel pan HDAC inhibitor resminostat in hepatocellular carcinoma cells.
    Fu M; Shi W; Li Z; Liu H
    Biochem Biophys Res Commun; 2016 Sep; 477(4):527-533. PubMed ID: 27144317
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacological or transcriptional inhibition of both HDAC1 and 2 leads to cell cycle blockage and apoptosis via p21
    Zhou H; Cai Y; Liu D; Li M; Sha Y; Zhang W; Wang K; Gong J; Tang N; Huang A; Xia J
    Cell Prolif; 2018 Jun; 51(3):e12447. PubMed ID: 29484736
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synergistic antitumor effect of histone deacetylase class IIa inhibitor with lenvatinib in hepatocellular carcinoma.
    Ito R; Miyanishi K; Kubo T; Hamaguchi K; Osuga T; Tanaka S; Ohnuma H; Murase K; Takada K; Nagayama M; Kimura Y; Mizuguchi T; Takemasa I; Kato J
    Hepatol Int; 2023 Jun; 17(3):735-744. PubMed ID: 36738397
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Radiosensitization effect by HDAC inhibition improves NKG2D-dependent natural killer cytotoxicity in hepatocellular carcinoma.
    Liu YF; Chiang Y; Hsu FM; Tsai CL; Cheng JC
    Front Oncol; 2022; 12():1009089. PubMed ID: 36185276
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The HDAC Inhibitor Quisinostat (JNJ-26481585) Supresses Hepatocellular Carcinoma alone and Synergistically in Combination with Sorafenib by G0/G1 phase arrest and Apoptosis induction.
    He B; Dai L; Zhang X; Chen D; Wu J; Feng X; Zhang Y; Xie H; Zhou L; Wu J; Zheng S
    Int J Biol Sci; 2018; 14(13):1845-1858. PubMed ID: 30443188
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Caveolin-mediated cytosolic delivery of spike nanoparticle enhances antitumor immunity of neoantigen vaccine for hepatocellular carcinoma.
    Lin Z; Jiang C; Wang P; Chen Q; Wang B; Fu X; Liang Y; Zhang D; Zeng Y; Liu X
    Theranostics; 2023; 13(12):4166-4181. PubMed ID: 37554274
    [No Abstract]   [Full Text] [Related]  

  • 17. Targeting histone deacetylase 4/ubiquitin-conjugating enzyme 9 impairs DNA repair for radiosensitization of hepatocellular carcinoma cells in mice.
    Tsai CL; Liu WL; Hsu FM; Yang PS; Yen RF; Tzen KY; Cheng AL; Chen PJ; Cheng JC
    Hepatology; 2018 Feb; 67(2):586-599. PubMed ID: 28646552
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Platycodin D reverses histone deacetylase inhibitor resistance in hepatocellular carcinoma cells by repressing ERK1/2-mediated cofilin-1 phosphorylation.
    Hsu WC; Ramesh S; Shibu MA; Chen MC; Wang TF; Day CH; Chen RJ; Padma VV; Li CC; Tseng YC; Huang CY
    Phytomedicine; 2021 Feb; 82():153442. PubMed ID: 33412494
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of a novel histone deacetylase inhibitor in murine models of hepatocellular carcinoma.
    Lu YS; Kashida Y; Kulp SK; Wang YC; Wang D; Hung JH; Tang M; Lin ZZ; Chen TJ; Cheng AL; Chen CS
    Hepatology; 2007 Oct; 46(4):1119-30. PubMed ID: 17654699
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatocellular Carcinoma Cells Up-regulate PVRL1, Stabilizing PVR and Inhibiting the Cytotoxic T-Cell Response via TIGIT to Mediate Tumor Resistance to PD1 Inhibitors in Mice.
    Chiu DK; Yuen VW; Cheu JW; Wei LL; Ting V; Fehlings M; Sumatoh H; Nardin A; Newell EW; Ng IO; Yau TC; Wong CM; Wong CC
    Gastroenterology; 2020 Aug; 159(2):609-623. PubMed ID: 32275969
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.